Transformative Therapeutics Targeting Orphan Diseases
Who We Are
SteroTherapeutics is pursuing novel drug therapies for orphan diseases, or diseases that are often life-threatening, and which affect fewer than 200,000 people in the United States. Our mission is to develop treatments that also have the potential to treat more common, large-market diseases.
We have established partnerships with some of the world’s leading academic research institutions and organizations.
Our lead program, ST-002 targets Cushing's syndrome. Cushing’s is caused by elevated levels of cortisol, which can manifest in obesity, diabetes, hypertension, cardiovascular disease, and immune dysfunction. Cushing's, an orphan disease, is poorly served by currently available therapies with limited efficacy and deleterious side effects. SteroTherapeutics entered into a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) to develop a novel treatment for Cushing’s syndrome patients. ST-002 may also have the potential to treat non alcoholic steatohepatitis, or NASH, an advanced form of non-alcoholic fatty liver disease that impacts up to 6% of the world’s population, or nearly 500 million people.
Primary Sclerosing Cholingitis
The second program, ST-003, is targeting the treatment of Primary Sclerosing Cholingitis (PSC). PSC is a rare, heterogeneous, immune inflammatory disorder of the bile ducts resulting in cholestasis due to strictures of the intrahepatic and and extrahepatic bile ducts. Although the great majority of PSC patients have inflammatory bowel disease (IBD), only ~ 5% of IBD patients will develop PSC and the underlying causes of the association remains poorly understood. However, ST-003 may have the potential to treat
the PSC comorbid IBD, as well as IBD itself, which affects an estimated 3.1 million adults in the US alone, or 1.3% of the US adult population.
SteroTherapeutics is also developing ST-004 a treatment for multiple myeloma with a highly selective novel matrix metallaoproteinase-13 (MMP-13) inhibitor licensed from the Lee H. Moffitt Cancer Center and the Florida Atlantic University Institute for Human Health and Disease Intervention. ST-004 reduces both osteoclastogenesis and osteoclast activity with no apparent off-target MMP inhibition-related adverse events. Unlike other MMP inhibitors, ST004 exhibits no collagenolysis or the multiple skeletal syndrome that limit the use of other MMP inhibitors.
May 31, 2022
SteroTherapeutics Granted Orphan Drug Designation to ST-003, a Novel Drug Candidate for the Treatment of Primary Sclerosing Cholangitis
March 29, 2022
Sterotherapeutics Signs Licensing Agreement Aimed to Improve the Treatment of Multiple Myeloma